- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05733871
Evaluation of the Effectiveness of Standard and Innovative Products That Represent a Substitute Meal for Weight Management in a Reduction Diet
Randomized Stratified Controlled Clinical Study for Evaluate the Effectiveness of a Diet Program Designed for Reduce Body Weight Using Standard and Innovative Products
Study Overview
Status
Conditions
Detailed Description
In the last few decades, there has been an increase in the number of obese people to the level of a global epidemic as a result of inadequate diet, sedentary lifestyle, but also genetic predispositions. The World Health Organization (WHO) declared obesity to be the biggest, global, chronic health problem in adults, that is increasingly becoming a more serious problem than malnutrition.On the other hand, obesity is a risk factor for the development of contemporary non-infectious diseases today that account for more than 80% of mortality in developed countries, such as vascular disease, diabetes and respiratory diseases such as asthma.
This trend is also recorded in Croatia, both in adult population and in children if the data from 2003 and 2015 are being compared, while according to data from 2019, almost two thirds of the adult population in Croatia were overweight or obese (42% overweight, 23% obese).
In cooperation with Podravka, Belupo has developed a standard and innovative product line. Products are replacing one or more one or more daily meals, and thay must comply with Regulation 2016/1413 requirements related to energy value, content and composition of fats and proteins, the amount of vitamins and minerals in this type of products.
The standard product line contains common ingredients and this type of product already exists on world markets, while the innovative product line differs from the standard one by implementing raw materials that are considered better sources of potentially bioactive components.
The study for a group of adult participants was designed in such a way that the participants in the initial stage follow a low-calorie diet of about 1000 - 1100 kcal, whereby 5 daily meals are replaced with meal replacements in the reduction diet (active group and active control) (intensive stage). In subsequent stages, subjects gradually increase their energy intake and gradually substitute meal replacement product (MRP) with regular nutritionally profiled meals (active stage and maintenance stage). The final (stable) stage represents the stage in which, in addition to one meal replacement per day, the usual meals designed by the nutritionists of Belupo and the Culinary Center of Podravka are consumed, where education and nutrition counseling is also carried out.
Study entry stage (0-2 weeks): subjects are recruited respecting the inclusion and exclusion criteria. Recruitment is carried out by a doctor. During this stage, subjects replace standard meals with meal replacement products and reduce energy intake to a final defined intake depending on the group of subjects.
36 participants in a ratio of 1:1:1
- active group - 12
- active control (positive control group) - 12
- control group (negative control group) - 12
The daily energy intake is defined at around 1000-1100 kcal per day, and counseling on nutrition and physical activity is carried out.
- Intensive stage (2-14 weeks) about 1000 - 1100 kcal/day 5 MRP (200-220 kcal per product) + 1 salad (20 kcal per portion) + water/unsweetened tea.
- Active stage (14-21 weeks) 1100-1200 kcal/day 3 MRP (200-220 kcal per meal) + 2 regular meals (200-280 kcal) + water/unsweetened tea.
- Maintenance stage (21-28 weeks): 1200-1500 kcal/day 2 MRP (200-220 kcal per meal) + 3 regular meals (260-350 kcal) + water/unsweetened tea
- Stable stage (28-40 weeks): 1500-2000 kcal 1 MRP (200-220 kcal per meal) + 4 regular meals (approx. 320-450 kcal) + water/unsweetened tea Usual meals can also contain snacks with lower energy values, but it is important to consume approx. 1300-1800 kcal per day with usual foods.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mirjana Turkalj, Prof., MD
- Phone Number: +38516391164
- Email: mturkalj@bolnica-srebrnjak.hr
Study Locations
-
-
-
Zagreb, Croatia, 10000
- Recruiting
- Children's Hospital Srebrnjak
-
Contact:
- Mirjana Turkalj, MD, PhD
- Phone Number: +38516391164
- Email: mturkalj@bolnica-srebrnjak.hr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults aged 18-60
- both sexes
- BMI >27 kg/m2
- signed informed consent
Exclusion Criteria:
- significant comorbidities: uncontrolled diabetes mellitus requiring insulin therapy and other endocrine disorders, cardiovascular disorders and other chronic diseases (including malignancies), chronic inflammatory diseases of the gastrointestinal tract, mental disorder
- people who are currently on or have recently went through an weight loss program (in the past 3 months)
- people who in the past 6 months had an unwanted and uncontrolled loss of body weight >5%
- people who underwent bariatric surgery in the past 6 months.
- people using drugs that increase or decrease appetite
- permanent therapy with steroid drugs, antidepressants, cytostatics, hormone therapy, beta blockers, etc.
- people with eating disorders (bulimia)
- alcohol and drug addicts
- pregnancy, breastfeeding
- unstable thyroid disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active group
Participants use the innovative line of products intended for body weight reduction, that represent a meal replacement for weight management
|
standard product line contains common ingredients and this type of product already exists on world markets
|
|
Active Comparator: Active control
Participants use the standard line of products intended for weight reduction that represent a meal replacement for weight management with already proven clinical effectiveness (positive control).
|
innovative product line contains raw materials that are considered better sources of potentially bioactive components
|
|
No Intervention: Control group
Participants receive personalized advice on proper nutrition for a reduction diet in which they use common food.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
BM/FM
Time Frame: After 40 weeks
|
To determine the effectiveness of a weight change diet program based on an innovative and standard product line through actual reduction of the body mass (BM) / fat mass (FM) of the participants in relation to their pre - trial body mass(BM)/fat mass (FM).
|
After 40 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anthropometric measurements
Time Frame: measurements at each examination - every 2 weeks up to week 21 and every 4 weeks from week 21 to week 40
|
Change in anthropometric measurements- waist and hip circumference and waist/hip ratio and waist/height ratio Measurements of participants' waist, hip and height in meters will be taken. This multiple measurements will be aggregated and presented in ratio waist [meter] / hip [meter] and ratio waist [meter] / height [meter] |
measurements at each examination - every 2 weeks up to week 21 and every 4 weeks from week 21 to week 40
|
|
Lipid profile (triglycerides, total cholesterol, HDL, LDL)
Time Frame: at the beginning of the study and after 3, 6 and 9 months
|
Change of the cholesterol test/lipid panel/lipid profile (change in HDL/LDL ratio) compared to initial values
|
at the beginning of the study and after 3, 6 and 9 months
|
|
Questionnaire on quality of life
Time Frame: at the beginning of the study (1st week) and at the end (40th week)
|
The questionnaire consists of descriptive system and visual analogue scale. The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The visual analogue scale records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The questionnaire is in Croatian language, with a valid and accurate translation of the corresponding original document. |
at the beginning of the study (1st week) and at the end (40th week)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KK.01.1.1.07.0075_1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Body Weight
-
Oslo University HospitalMayo Clinic; Sorlandet Hospital HF; The Hospital of Vestfold; University of TwenteActive, not recruiting
-
Fred Hutchinson Cancer CenterCompletedWeight Loss | Weight, BodyUnited States
-
Pusan National University HospitalCompletedWeight Change, Body
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Erik Ramirez LopezCompletedWeight Loss | Body CompositionMexico
-
Virta HealthCompleted
-
University of TennesseeMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases...CompletedSmoking Cessation | Weight Change, BodyUnited States
-
University of CopenhagenCompleted
-
University of LeedsDietary Assessment LtdCompletedWeight Loss | Colorectal Surgery | Weight Change, Body | Gastroenterology SurgeryUnited Kingdom
-
North Dakota State UniversityThe Cleveland Clinic; Neuropsychiatric Research InstituteUnknown
Clinical Trials on meal replacement product- STANDARD PRODUCT
-
Children's Hospital SrebrnjakBelupo; Podravka d.d.Recruiting
-
New York Obesity and Nutrition Research CenterColumbia University; St. Luke's-Roosevelt Hospital CenterCompleted
-
Midwest Center for Metabolic and Cardiovascular...Pharmavite LLCNot yet recruiting
-
Abbott NutritionCompletedType 2 Diabetes MellitusUnited States
-
Abion IncCompletedSolid TumorKorea, Republic of
-
Abbott NutritionCompleted
-
RAI Services CompanyNot yet recruitingSmoking | Tobacco Use | Tobacco Smoking | Smoking Behaviors
-
British American Tobacco (Investments) LimitedCompletedTobacco Use | Tobacco SmokingUnited States